Health Trials

HER2-positive Colorectal Cancer

3

Review clinical trials related to HER2-positive Colorectal Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Participants needed: 383
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iambic Therapeutics, IncUpdated: Jun 4, 2026Locations: 53
Eligibility criteria

Age ≥ 18 years [+7]

Clinically significant cardiac disease [+8]

Read more
Status: Not yet recruiting

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.

Participants needed: 123
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Feb 3, 2026
Eligibility criteria

Age≥18 years old. [+9]

Participants who have previously been treated with an anti-HER2 ADC loaded with... [+15]

Read more
Status: Not yet recruiting

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 （a PD-L1/CTLA-4 targeted bispecific antibody）.

Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Aug 21, 2023Locations: 1
Eligibility criteria

Participants are able to comprehend the informed consent information and sign th... [+10]

Subjects with untreated active brain metastases or leptomeningeal metastases; if... [+18]

Read more